Overview

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Status:
Unknown status
Trial end date:
2019-06-25
Target enrollment:
Participant gender:
Summary
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College